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carcinoma by suppressing CDK2AP1 expression
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Abstract 
Background: The aberrant expression of microRNAs (miRNAs) has been found in various types of cancer. miR-205 
was reported to be upregulated in laryngeal squamous cell carcinoma (LSCC) tissues, however, the mechanisms by 
which miR-205 functions as a regulator of LSCC are largely unknown.
Results: In this study, Real-time qPCR and Western blot assay showed that expression of miR-205 was upregulated 
and expression of cyclin-dependent kinase 2-associated protein 1 (CDK2AP1) was downregulated in LSCC tissues. 
The expression levels of miR-205 were negatively related to those of CDK2AP1 in LSCC tissues and cell lines. Moreo-
ver, we found that miR-205 was the upstream regulator of CDK2AP1 and could suppress the CDK2AP1 expression in 
LSCC cells. 3-(4,5-dimethylthiazal-2-yl)-2,5-diphenyl-tetrazolium bromide assays and transwell invasion assay were 
performed to test the proliferation and invasion of LSCC cells. Gelatin zymography was used to detect the activity of 
MMP2 and MMP9. CDK2AP1, c-Myc and CyclinD1 expression in cells was assessed with Western blotting. We found 
that miR-205 was the upstream regulator of CDK2AP1 and could suppress the expression of CDK2AP1 in LSCC cells. 
In addition, miR-205 significantly induced cell proliferation and invasion by suppressing CDK2AP1 expression. Con-
sistent with miR-205 inhibitors, overexpressed CDK2AP1 suppressed the activity of MMP2 and MMP9 and c-Myc and 
CyclinD1 expression in LSCC cells.
Conclusion: These findings help us to better elucidate the molecular mechanisms of LSCC progression and provide 
a new theoretical basis to further investigate miR-205 as a potential biomarker and a promising approach for LSCC 
treatment.
Keywords: miR-205, Laryngeal squamous cell carcinoma (LSCC), CDK2AP1, c-Myc, CyclinD1
© 2015 Zhong and Xiong. This article is distributed under the terms of the Creative Commons Attribution 4.0 International 
License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any 
medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons 
license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.
org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Laryngeal squamous cell carcinoma (LSCC) is one of the 
most common cancers with high incidence and mortality 
[1]. In 2011, LSCCs accounted for approximately 0.7 % of 
all new cancer diagnoses and leaded to 0.6 % of all can-
cer-related deaths [2]. Despite improvements of diagnosis 
and treatment of LSCCs, the survival rate of patients with 
LSCC has not improved dramatically in the past 20 years 
[3]. Therefore, it is urgent to elucidate the molecular 
mechanisms of LSCC proliferation and metastasis, which 
will provide important insights and help us find new 
diagnostic and therapeutic approaches to this disease and 
improve the prognosis of LSCC patients.
MicroRNAs (miRNAs), as a class of small (22-nucleo-
tide) non-coding RNAs, have been identified to be aber-
rantly expressed in several human malignancies [4]. 
miRNAs regulate gene expression by binding to the 
3′untranslated region (3′-UTR) of their target mRNAs, 
modulating mRNA stability and/or translation [5]. Pre-
vious studies have identified a number of miRNAs that 
show aberrant expression in LSCC [6–9]. For instance, 
miR-129-5p is upregulated in primary LSCC tumors and 
functions as an oncogene in LSCC by repressing APC 
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[8]. miR-139 is down regulated in LSCC tissues and tar-
gets CXCR4 and inhibits proliferation and metastasis of 
LSCC [10]. miR-19a is overexpressed in LSCC and corre-
lated with prognosis and apoptosis of LSCC by regulating 
TIMP-2 expression [11]. Therefore, further exploration 
of the expression and function of miRNAs will provide 
insight into the pathogenesis and progression of LSCC.
Recently, an increasing number of studies have dem-
onstrated that the expression of miR-205 is deregulated 
in various cancers [12, 13]. For example, downregulated 
miR-205 expression was observed in breast cancer, and it 
regulated proliferation and invasion of breast cancer cells 
by targeting HMGB3 [12]. Significantly lower miR-205 
expression levels was also found in prostate cancer tis-
sues and cell lines, and miR-205 exerts tumor-suppressive 
functions in human prostate through down-regulation of 
protein kinase cepsilon [14]. miR-205 was also found to 
be downregulated in esophageal cancer [15]. Meanwhile, 
recent studies showed the increased expression of miR-
205 in lung cancer [16] and endometrial endometrioid 
carcinoma (EEC) [17]. A significant increase in miR-205 
staining intensity was also observed from malignant 
tumors in head and neck tissue array [18]. Recently, miR-
205 was reported to be upregulated in LSCC tissue [19], 
however, the role and underlying molecular mechanisms 
of miR-205 in LSCC remains unclear.
Cyclin-dependent kinase 2-associated protein 1 
(CDK2AP1), also named as DOC-1 (deleted in oral can-
cer-1), is a growth suppressor originally isolated from 
normal hamster oral keratinocytes [20]. There is evidence 
to suggest that CDK2AP1, as an inhibitor of CDK2 and 
hence G1/S transition, is expected to involve cell cycle 
progression [21]. In addition, recent studies showed that 
CDK2AP1 mediates the growth suppressing signal from 
TGF-β [22]. Recently, decreased CDK2AP1 expression 
was shown to correlate with tumor metastasis [23–25] 
and survival in patients with cancer [26]. CDK2AP1 
negatively regulates cell cycle progression and cell pro-
liferation as a target for silencing or downregulation 
in tumorigenesis. Given the significant association of 
CDK2AP1 expression with tumorigenesis, CDK2AP1 
may play a role in oncogenesis and serves as a molecular 
target for cancer therapy. However, to date, the specific 
roles of CDK2AP1 in LSCC have not yet been reported.
The present study showed that miR-205, as an onco-
gene, was the upstream regulator of CDK2AP1 in LSCC 
cells. miR-205-mediated CDK2AP1 involves cell prolif-
eration and invasion by increasing the activity of MMP2 
and MMP9 and down-regulating c-Myc and CyclinD1 
expression in LSCC cells.
Results
miR‑205 is negatively associated with CDK2AP1 in clinical 
LSCC tissues
Next, we analyzed the miR-205 and CDK2AP1 expression 
in 10 paired clinical LSCC and adjacent noncancerous 
tissues using qRT-PCR and western blot. When com-
pared with their noncancerous counterparts, significant 
upregulation of miR-205 (Fig.  1a) and downregulation 
of CDK2AP1 (Fig. 1b and c) were observed in all the 10 
LSCC samples. Then we assessed the correlation between 
miR-205 and CDK2AP1. As expected, we found that the 
levels of miR-205 exhibited a significant negative correla-
tion with the levels of CDK2AP1 mRNA (Pearson’s corre-
lation coefficient of −0.7604, p < 0.01) (Fig. 1d). Overall, 
our finding indicates that the levels of miR-205 are nega-
tively associated with those of CDK2AP1 mRNA in clini-
cal LSCC tissues.
miR‑205 was the upstream regulator of CDK2AP1
Previous studies showed that miR-205 was upregulated 
in LSCC tissue [19]. Here, we detected the expression of 
miR-205 in four LSSC cell lines (TU212, Hep-2, TU686 
and M2e). As shown in Fig. 2a, the real-time PCR assay 
showed that the expression level of miR-205 was mark-
edly upregulated in Hep-2 cell line compared with other 
LSSC cell lines (TU212, TU686 and M2e).
The miRNA target prediction websites http://www.
microRNA.org and TargetScan showed that CDK2AP1 is 
the target gene of miR-205. To further confirm CDK2AP1 
is a potential downstream target gene of miR-205 in 
LSCC cells, we detected the expression of CDK2AP1 in 
four LSSC cell lines (TU212, Hep-2, TU686 and M2e) 
and the effects of miR-205 on CDK2AP1 expression. 
As shown in Fig.  2b and c, mRNA expression level of 
CDK2AP1 was significantly lower in Hep-2 cell line, in 
comparison with the expression levels in TU212, TU686 
and M2e cell lines, which was consistent with protein 
expression levels of CDK2AP1 using western blot analy-
sis. So Hep-2 cell line was used for the following further 
analysis.
Furthermore, we silenced miR-205 or overex-
pressed CDK2AP1 to detect the interaction of miR-
205 with CDK2AP1. As shown in Fig.  2d, miR-205 
inhibitors silenced miR-205 expression significantly, 
however, overexpressed CDK2AP1 had no effect on 
miR-205 expression. Fig 2e showed that miR-205 inhibi-
tors induced CDK2AP1 expression evidently. Taken 
together, these results indicated that CDK2AP1, as an 
oncogene, was a potential downstream gene of miR-205 
in LSCC.
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miR‑205 promotes cell proliferation and invasion 
by suppressing CDK2AP1 expression in LSCC
To evaluate the impact of miR-205 on LSCC cell invasion, 
transwell invasion assays were employed in this study. 
The results showed that silenced miR-205 decreased the 
invasion of Hep-2 cells, which was consistent with over-
expressed CDK2AP1 (Fig.  3a). Figure  3b showed the 
effects of miR-205 and CDK2AP1 on the proliferation of 
LSCC cells using a 3-(4,5-dimethylthiazal-2-yl)-2,5-di-
phenyl-tetrazolium bromide (MTT) assay. Consistent 
with miR-205 inhibitors, overexpressed CDK2AP1 signif-
icantly decreased the proliferation ability of HCC cells at 
48 and 72 h, compared with control group (Fig. 3b).
miR‑205 regulates activity of MMP2 and MMP9 
by suppressing CDK2AP1 expression in LSCC
Furthermore, we detected the effects of miR-205 and 
CDK2AP1 on the activity of MMP2 and MMP9 in 
Hep-2 cells. As shown in Fig.  3c, the activity of MMP2 
and MMP9 was significantly downregulated by miR-205 
inhibitors and CDK2AP1 compared to control group. It 
suggested that miR-205 promotes the activity of MMP2 
and MMP9 by suppressing CDK2AP1 expression in 
LSCC cells.
miR‑205 induces c‑Myc and CyclinD1 expression 
by suppressing CDK2AP1 expression
CDK2AP1 is a cell cycle regulator, it upregulates cell 
cycle inhibitory genes and suppresses G1-S transition 
[27]. c-Myc, and CyclinD1 are oncoproteins that play 
an important role in cell proliferation, cell cycle regula-
tion, and invasion, respectively [28, 29]. In the present 
study, Western blotting was used to investigate whether 
miR-205 regulates the expression of c-Myc and CyclinD1 
through suppressing CDK2AP1 expression (Fig.  4). The 
results revealed that the expression levels of c-Myc and 
CyclinD1 in miR-205 inhibitors group and overexpressed 
CDK2AP1 group were significantly lower than that in 
control group. These results provide further support of 
the inhibitory role that miR-205 plays in the proliferation, 
invasion of LSCC cells by targeting CDK2AP1.
Discussion
miR-205 is involved in the genesis and progression of 
human malignancies. Dysregulation of miR-205 expres-
sion was found in various tumors and implicated in the 
regulation of cell apoptosis, proliferation and metasta-
sis. Several studies have shown that miR-205 is down-
regulated in different tumor types: Yin et  al. found that 
Fig. 1 The expression of miR-205 and CDK2AP1 in NPC tissue. a miR-205 expression levels was examined by qRT-PCR in 10 cases of clinical LSCC 
tissues and paired non-tumorous tissues. b CDK2AP1 expression levels was examined by qRT-PCR in 10 cases of clinical LSCC tissues and paired 
non-tumorous tissues. c CDK2AP1 expression levels was examined by western blot in 10 cases of clinical LSCC tissues and paired non-tumorous 
tissues. d Correlation of miR-205 levels with CDK2AP1 levels was examined by qRT-PCR in 10 cases of clinical LSCC tissues (Pearson’s correlation 
coefficient, r = −0.7604)
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miR-205 is significantly downregulated in gastric cancer 
tissues, compared with adjacent normal tissues [30]. miR-
205 is also up-regulated in breast cancer [12], prostate 
cancer [14], esophageal cancer [15] and head and neck 
carcinomas [31]. In contrast, miR-205 expression has 
been found to be up-regulated in esophageal squamous 
cell carcinoma [32]. Recent studies showed the increased 
expression of miR-205 in lung cancer [16] and endome-
trial endometrioid carcinoma (EEC) [17]. Although Tian’s 
work is contradictory and shows that miR-205 expression 
is downregulated in LSCC [33], Cao et al. confirmed that 
miR-205 showed higher expression in (LSCC) tissue than 
in adjacent normal tissues [19], Kimura et  al. reported 
high expression levels of miR-205 in both malignant and 
benign squamous epithelia [34]. In this study, real-time 
qPCR and western blot assay showed that expression of 
miR-205 was upregulated and expression of CDK2AP1 
was upregulated in LSCC tissues, and the expression 
levels of miR-205 were negatively related to those of 
CDK2AP1 in LSCC tissues. Next, we detected the expres-
sion of miR-205 in four LSSC cell lines (TU212, Hep-2, 
TU686 and M2e) and found that miR-205 expression in 
Hep-2 cell line was higher compared with other LSSC cell 
lines (TU212, TU686 and M2e). miR-205 inhibitors sup-
pressed LSCC proliferation and invasion. These results 
indicated that miR-205, as an oncogene, regulated prolif-
eration and invasion of LSCC.
CDK2AP1, corresponding to the gene doc-1, is an 
S-phase-associated growth suppressor that binds with 
DNA polymerase A/primase and/or CDK2 [20, 35]. 
Recently, emerging evidence suggests that loss or reduced 
expression of CDK2AP1 might contribute to the tumori-
genesis in many types of malignancies including esopha-
geal carcinoma, oral cancer, prostate cancer, colorectal 
cancer and gastric cancer [22, 25, 36–39]. In this study, 
we detected the expression of CDK2AP1 in four LSSC 
cell lines (TU212, Hep-2, TU686 and M2e) and found 
that expression levels of CDK2AP1 was significantly low-
est in Hep-2 cell lines, in comparison with the expres-
sion levels in TU212, TU686 and M2e cell lines. miRNAs 
were found to exert their biological functions by target-
ing its target genes. Recently, CDK2AP1 was reported 
as the target gene of miR-21 in malignant human oral 
keratinocyte [40]. However, no other miRNA was found 
Fig. 2 miR-205 was the upstream regulator of CDK2AP1. a miR-205 expression in LSCC cell lines. qRT-PCR analysis revealed miR-205 expression 
in TU212, TU686, M2e and Hep-2 cell lines. Error bars represent ± S.E. and ap < 0.01 versus TU212 cells. bp < 0.01 versus M2e cells. cp < 0.01 versus 
TU686 cells. b qRT-PCR analysis revealed CDK2AP1 expression in miR-205 expression in TU212, TU686, M2e and Hep-2 cell lines. c Western blot 
analysis CDK2AP1 expression in miR-205 expression in TU212, TU686, M2e and Hep-2 cell lines.Error bars represent ± SD and ap < 0.01 versus TU212 
cells. bp < 0.01 versus M2e cells. cp < 0.01 versus TU686 cells. d qRT-PCR analysis revealed the effect of miR-205 and CDK2AP1 on miR-205 expres-
sion. e Western blot analysis revealed the effect of miR-205 and CDK2AP1 on CDK2AP1 expression. Hep-2 cells were transfected with miR-205 (miR-
205 group) or miR-205 negtive control (miR-205 NC group) or CDK2AP1 (CDK2AP1 group). Error bars represent ± SD and *p < 0.01 versus control 
group
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to be the regulator of CDK2AP1. In this study, CDK2AP1 
expression was suppressed by miR-205, indicating that 
CDK2AP1 is a downstream gene of miR-205 in LSCC. 
Consistent with other tumors, overexpressed CDK2AP1 
also suppressed cell proliferation and invasion in LSCC. 
Moreover, overexpressed CDK2AP1 reduced the activity 
of MMP2 and MMP9 in LSCC evidently.
It has been demonstrated that CDK2AP1, as cell cycle 
regulator, is an important candidate target for therapeu-
tic intervention [41, 42]. c-Myc and cyclin D1 are cell 
cycle regulatory proteins and reported to involve tumori-
genesis [43–45]. In this study, attention is also paid to the 
issues regarding association between the antitumor activ-
ity of CDK2AP1 and expression of c-Myc and cyclin D1 
gene and our finding shows that miR-205 inhibitors and 
ectopic CDK2AP1 reduced the expression of c-Myc and 
cyclin D1 in LSCC cells.
Conclusion
Our findings strongly suggest that CDK2AP1 is a down-
stream gene of miR-205 and facilitates important regula-
tory roles in cell proliferation and invasion progression 
of LSCC via c-Myc/cyclin D1 pathway. Hence, this study 
extends our current knowledge on oncogenesis of LSCC 
and indicates that CDK2AP1 may serve as a new molecu-
lar target for LSCC therapy.
Methods
Human tissue specimens
Ten clinical LSCC tissues and their corresponding non-
cancerous tissues used in this study were obtained 
from Wuhan Union Hospital of Tongji Medical College 
Fig. 3 miR-205 promotes cell proliferation and invasion by suppressing CDK2AP1 expression in LSCC. a Transwell invasion assay revealed the effects 
of miR-205 and CDK2AP1 on LSCC invasion. b MTT assay revealed the effects of miR-205 and CDK2AP1 on LSCC proliferation. c Gelatin zymography 
assay revealed effects of miR-205 and CDK2AP1 on activity of MMP2 and MMP9 in LSCC
Fig. 4 miR-205 induces the expression of c-Myc and CyclinD1 by 
targeting CDK2AP1. Hep-2 cells were transfected with miR-205 mim-
ics (miR-205 group) or miR-205 negative control (miR-205 NC group) 
or CDK2AP1 (CDK2AP1 group). Forty-eight hours later, proteins were 
harvested for Western blotting; GAPDH served as an internal control. 
Error bars represent ± SD *p < 0.01 versus control and NC
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(Hubei, China) after surgical resection. Informed con-
sents were obtained from each patient to approve the use 
of their tissues for research purposes. The study protocol 
was approved by the Institute Research Ethics Commit-
tee at Tongji Medical College.
Cell culture and transfection
The LSCC cell lines TU212, Hep-2, TU686 and M2e 
were used in this study. All cells were cultured DMEM 
medium (Invitrogen, Carlsbad, CA, USA) supplemented 
with 10  % fetal bovine serum (HyClone, Logan, Utah, 
USA) and 1 % penicillin/streptomycin and incubated in a 
humidified (37 °C, 5 % CO2) incubator.
The miR-205 inhibitors and negative control molecules 
were synthesized by GenePharma Co., Ltd. (Shanghai, 
China), added to culture media at a final concentration of 
100 nM and transfected into cells using Lipofectamine™ 
2000 (Invitrogen Life Technologies) according to the 
manufacturer’s instructions.
Quantitative real‑time PCR
Total RNA was isolated from Hep-2 cell lines using Tri-
zol reagent (Invitrogen). The expression of miR-205 was 
quantified by qRT-PCR using TaqMan microRNA assays 
(Applied Biosystems, Carlsbad, CA, USA) and normalized 
to U6B. The expression of CDK2AP1 was quantified by 
qRT-PCR using SYBR-Green assays (Applied Biosystems) 
and normalized to β-actin. Gene expression was calcu-
lated using the 2−ΔCt method. The primers were as follows: 
miR-205: 5′-UCCUUCAUUCCACCGGAGUCUG-3′ 
and miR-205-inhibitors: 5′-CAGACUCCGGUGGAAU 
GAAGGA-3′; miR-205 NC: forward primer: 5′-UUCUCC 
GAACGUGUCACGUTT-3′ and reverse primer: 5′-ACG 
UGACACGUUCGGAGAATT-3′. CDK2AP1, forward 
primer: 5′-TAGTAGCCGGTTCCCATTTG-3′ and reverse 
primer: 5′-TTAGGTTTGGTGGGTTGCTC-3′.
Western blot analysis
Whole cell extracts were prepared with a cell lysis reagent 
(Sigma-Aldrich, St. Louis, MO, USA) according to the 
manual, and then, the protein was quantified by a BCA 
assay (Pierce, Rockford, IL, USA). Then, the protein sam-
ples were separated by SDS-PAGE (10 %) and detected by 
Western blot using polyclonal (rabbit) anti-CDK2AP1, 
anti-c-Myc and anti-cyclinD1 antibody (Santa Cruz Bio-
technology, Santa Cruz, CA, USA). Goat anti-rabbit IgG 
(Pierce, Rockford, IL, USA) secondary antibody conju-
gated to horseradish peroxidase and ECL detection systems 
(SuperSignal West Femto, Pierce) were used for detection.
Cell survival assay
The MTT assay was used to estimate cell viability [46]. 
Briefly, cells were plated at a density of 1 × 104 cells per 
well in 96-well plates. After exposure to specific treat-
ment, the cells were incubated with MTT at a final 
concentration of 0.5  mg/ml for 4  h at 37  °C. After the 
removal of the medium, 150 mM DMSO solutions were 
added to dissolve the formazan crystals. The absorbance 
was read at 570 nm using a multi-well scanning spectro-
photometer reader. Cells in the control group were con-
sidered 100 % viable.
Invasion assay
The capability of cell invasion was examined by transwell 
invasion assay. Cells were cultivated to 80 % confluence 
on the 12-well plates. Then, we observed the procedures 
of cellular growth at 72  h. All the experiments were 
repeated in triplicate. The transwell migration chambers 
were used to evaluate cell invasion. Then cells invasing 
cells across the membrane were counted under a light 
microscope.
Gelatin zymography
MMP Zymography assay kit (for MMP-2 and MMP-9) 
(Applygen Technologie, China) was used to detect the 
activity of MMP2 and MMP9. Protein extracts and posi-
tive mixture were mixed with an equal volume of 2X 
SDS-PAGE non-reducing buffer, and electrophoresed on 
8 % SDS polyacrylamide gels containing 2 mg/ml of gela-
tin. Gels were then washed twice for 30 min in buffer A 
at room temperature, and incubated for 4 h at room tem-
perature in incubation buffer B. Gels were then stained 
for 2  h with 0.25  % Coomassie brilliant blue and then 
destained in destaining buffer (10 % acetic acid and 20 % 
methanol) for 60 min.
Statistical analysis
Each experiment was repeated at least three times. Data 
were shown as mean ± SD and analyzed using SPSS 18.0. 
Statistical comparisons between groups were analyzed 
using Student’s t test and a two-tailed p < 0.05 was con-
sidered to indicate statistical significance.
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